Physician profile
Julie Abraham
NPI 1548493935
$9,693.31
in general payments reported to CMS, 2019-2025
21 companies · $1,694 in 2025
The $1,694 reported for 2025 was more than what 96% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $216 · 2021: $138 · 2022: $1,004 · 2023: $969 · 2024: $5,672 · 2025: $1,694.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,250 · Entertainment: $85.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,249.75 |
| Entertainment | $85.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Visioneering Technologies, INC. | $4,372.82 | 2024 | |
| Bausch & Lomb Americas INC. | $1,130.84 | 2022-2025 | Xiidra, Miebo, Infuse |
| Alcon Vision LLC | $614.34 | 2022-2025 | Tryptyr, Simbrinza, Rhopressa |
| Visionary Optics LLC | $518.25 | 2023 | |
| Johnson & Johnson Vision Care, INC. | $426.88 | 2022-2024 | Acuvue |
| Sight Sciences, INC. | $327.26 | 2022-2023 | Omni Surgical System |
| Coopervision INC. | $295.23 | 2023-2025 | Myday Contact Lens, Onefit Contact Lens, Misight Contact Lens |
| Astellas Pharma US INC | $249.77 | 2024-2025 | Izervay |
| Oyster Point Pharma, INC. | $245.67 | 2023-2024 | Tyrvaya |
| Apellis Pharmaceuticals, INC. | $235.12 | 2024-2025 | Syfovre |
| Tarsus Pharmaceuticals, INC. | $176.23 | 2024-2025 | |
| Ocular Therapeutix, INC. | $143.42 | 2024 | Dextenza |
| Eyevance Pharmaceuticals LLC | $138.49 | 2021 | |
| Glaukos Corporation | $137.45 | 2023-2025 | Photrexa Viscous and Photrexa, Kxl System (Not Refurbished), Photrexa Cross-Linking Kit |
| Dompe US, INC. | $121.21 | 2025 | Oxervate |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $118.52 | 2025 | Vevye |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $116.05 | 2019 | |
| Novartis Pharmaceuticals Corporation | $114.01 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $99.93 | 2019 | |
| Optos, INC. | $85.01 | 2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Lilly USA, LLC | $26.81 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Abraham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.